Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Hybrid Multi-Mode Microplate Reader

By Drug Discovery Trends Editor | August 25, 2010

BioTek, a market leader in hybrid microplate detection technology, has released its newest product, the Synergy H1 Hybrid Multi-Mode Microplate Reader. This latest addition to its “patent-pending” product line expands the performance, versatility and flexibility offered by Hybrid Technology.

Synergy H1 is offered as highly flexible, high value monochromator-based Multi-Mode microplate reader for UV-Vis absorbance, top and bottom fluorescence, and luminescence assays that can be easily upgraded to a “hybrid” reader with the addition of a high performance filter module. This independent filter module with dichroic mirrors supports Fluorescence Polarization (FP), Time-Resolved Fluorescence (TRF), TR-FRET and BRET assays with ultra-high sensitivity.

Synergy H1 includes BioTek’s well recognized Gen5 Data Analysis Software for advanced reader control, data analysis, graphing, exporting and reporting. Additionally, Synergy H1 is compatible with BioTek’s Take3 Multi-Volume Plate that measures up to sixteen 2 µL samples, two BioCells or a standard cuvette for fast and simple multi-volume, multi-sample analysis.

“Synergy H1 provides robust performance and for the first time makes “Hybrid Technology” available to life science, academic and small biotechnology companies at a very competitive price,” notes Gary Barush, BioTek’s Director of Marketing and Sales. “The modular architecture means that customers can easily upgrade from a monochromator-based multi-mode reader to a hybrid reader offering true versatility and unlimited assay use.”

BioTek


Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE